肠道微生态与炎症性肠病  

Intestinal microbiome and inflammatory bowel disease

作　　者：兰平[1] 吴锦杰 何真[1] Lan Ping;Wu Jinjie;He Zhen(Department of Colorectal Surgery,The Six Affiliated Hospital,Sun Yat sen University,Guangzhou 510655,China)

机构地区：[1]中山大学附属第六医院结直肠肛门外科,广州510655

出　　处：《中华炎性肠病杂志（中英文）》2020年第1期2-6,共5页Chinese Journal of Inflammatory Bowel Diseases

基　　金：国家自然科学基金(81902938);中央高校基本科研业务费专项资金(19ykzd02);广州再生医学与健康广东省实验室临床创新研究项目(2018GZR0201005)。

摘　　要：炎症性肠病(IBD)是由遗传因素、肠道菌群和宿主免疫系统等多因素参与的慢性肠道炎性疾病,确切的病因和发病机制尚不清楚。肠道微生物的组成和功能改变可导致IBD的发生发展。在基因易感性患者中,失调的肠道菌群及其代谢产物通过与宿主的相互作用可引起肠道微免疫环境失调,破坏肠道的免疫耐受,最终诱发肠道炎症。本文总结和探讨肠道菌群在IBD中的作用机制,为IBD的预防及诊治提供理论依据。Inflammatory bowel disease(IBD)is a chronic inflammatory disease and involved multiple factors including host genetic factors,intestinal microbiome,and host immunity.But current understandings of etiology and pathogenesis remain unclear.Recent studies indicate the dysbiosis and altered function of microbial communities resulting in the development of IBD.In a specific host genetic context,the interplay among host,microbes and their metabolism can lead to a break in intestinal tolerance and homeostasis through various mechanisms.The aim of this review is to summarize current advances of gut microbiome linked to IBD pathogenesis,providing theoretical basis for the prevention and treatment of IBD.

关 键 词：炎症性肠病 肠道微生态 免疫 代谢物 治疗 

分 类 号：R57[医药卫生—消化系统]